Separation and Purification Columns

News
Article
Pharmaceutical TechnologyPharmaceutical Technology, August 2024
Volume 48
Issue 8

These columns offer fast run times, optimal separation efficiency, and reliable results.

Thermo’s DNAPac RP HPLC columns | Image Credit: Thermo Fisher Scientific

Thermo’s DNAPac RP HPLC columns | Image Credit: Thermo Fisher Scientific

The Thermo Scientific SurePac Bio 550 SEC MDi columns enable fast separations of adeno-associated virus (AAV) monomers and aggregates. The columns are designed with 3 µm monodisperse particles and inert (MDi) column hardware aimed at providing superior AAV monomer retention and higher resolution of aggregates in cell and gene therapies.

Editor’s note: this article was published in the Aug. 1, 2024 issue of Pharmaceutical Technology Europe®

These columns offer fast run times, optimal separation efficiency, and reliable results with the goal of accelerating time-to-market for novel therapeutics. In addition, Thermo’s DNAPac RP HPLC columns (pictured here) are offered in semi-preparative formats to enable scalability in the development of DNA/RNA oligonucleotides. The DNAPac RP semi-preparative columns are designed so that laboratories can navigate the expanding field of oligonucleotide therapies and precision medicine. The DNAPac RP semi-preparative column utilizes unique chemistry for enhanced performance across wide ranges of pH, temperature, and mobile-phase compositions, offering precise separations and sample purification.

Thermo Fisher Scientific

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Related Content